New imaging agent headed for clinical trial
Tumor Paint BLZ-100, a protein-linked dye derived from scorpion venom, lights up cancer cells to distinguish them from healthy cells during brain tumor surgery. The imaging agent, which was pioneered by Dr. Jim Olson at the Fred Hutchinson Cancer Research Center in Seattle, will be used in a clinical trial with brain tumor patients starting next year.
PBTF funds study that finds potential DIPG therapy
Researchers at Northwestern, funded in part by the Pediatric Brain Tumor Foundation, recently announced a new therapy for patients with diffuse intrinsic pontine gliomas, or DIPG. Because of their location on the brainstem, DIPGs are inoperable and chemotherapy and radiation treatments have had little success. The new therapy, using an experimental drug called GSKJ4, targets a genetic mutation in DIPG patients by inhibiting its tumor-forming consequences.
Cancer community concerned about EU proposal
A recent European Parliament resolution may impose that researchers be required to ask for a patient's ‘specific’ consent each time new research is carried out on already available data and/or tissues. The unintended consequence of the wording may put at stake the practice of retrospective clinical research, tissue banking and population-based cancer registries.
Childhood cancer survivors face more health issues in adulthood
According to a federally funded study led by researchers at St. Jude Children's Research Hospital, adult survivors of childhood cancer face significant health problems as they age. The study shows that these survivors are five times more likely than their siblings to develop new cancers beyond the age of 35. –Science Daily
Parents donate child’s tumor tissue to research
After losing their 6-year-old son to DIPG, parents Lenore and Trevor Wyant donated his tumor tissue to research, hoping to find answers for other children battling the disease. Because of donated tissue samples, scientists were able to conduct the studies that led to the discovery reported in 2012, that unique genetic mutations are present in 80 percent of DIPG samples. –USA Today